BRD4 and Familial prostate cancer: In an open-label Phase I clinical trial of the BRD4 inhibitor ODM-207 in 35 patients with solid tumors including castrate-resistant prostate cancer, no complete or partial responses were observed, and side effects such as thrombocytopenia, anorexia, nausea, diarrhea and fatigue were common, indicating that ODM-207 is not efficacious and has a narrow therapeutic window [78] (Table 3).